Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 792 Shares

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 792 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $146.04, for a total value of $115,663.68. Following the sale, the chief financial officer now owns 71,869 shares of the company’s stock, valued at approximately $10,495,748.76. This represents a 1.09 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, February 3rd, Michael Burkes Brophy sold 43,502 shares of Natera stock. The shares were sold at an average price of $176.88, for a total value of $7,694,633.76.
• On Wednesday, January 29th, Michael Burkes Brophy sold 4,335 shares of Natera stock. The stock was sold at an average price of $165.87, for a total value of $719,046.45.
• On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The shares were sold at an average price of $176.60, for a total transaction of $333,067.60.
• On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The stock was sold at an average price of $161.87, for a total transaction of $233,416.54.
• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The stock was sold at an average price of $171.98, for a total transaction of $162,693.08.
• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The shares were sold at an average price of $164.97, for a total transaction of $4,277,837.07.

Natera Stock Performance

Shares of NTRA stock opened at $149.63 on Friday. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 12-month low of $83.13 and a 12-month high of $183.00. The business’s 50 day moving average is $161.71 and its two-hundred day moving average is $149.27. The company has a market capitalization of $20.23 billion, a P/E ratio of -85.02 and a beta of 1.80.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. Analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on NTRA. BTIG Research reaffirmed a “buy” rating on shares of Natera in a research report on Friday, February 28th. Robert W. Baird lifted their target price on Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Royal Bank of Canada started coverage on shares of Natera in a report on Thursday, March 13th. They issued an “outperform” rating and a $251.00 price target on the stock. Morgan Stanley raised their price target on shares of Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Finally, The Goldman Sachs Group upped their price objective on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, Natera has a consensus rating of “Moderate Buy” and a consensus price target of $178.12.

Hedge Funds Weigh In On Natera

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. LRI Investments LLC purchased a new stake in shares of Natera during the fourth quarter worth about $29,000. Blue Trust Inc. boosted its holdings in Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after buying an additional 97 shares during the last quarter. Versant Capital Management Inc increased its stake in Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after buying an additional 166 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock valued at $52,000 after acquiring an additional 261 shares during the last quarter. Finally, Principal Securities Inc. lifted its position in shares of Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 59 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.